Gameto’s lead asset is a cell-based IVM tool, Fertilo, which is currently in late-stage development within the US.

Anthropic hopes Powerful AI will “match or exceed the cognitive capabilities of top human experts across scientific disciplines”.

British biotech generally raised more across public and private markets in Q3 2026, despite an overall downturn in the flow of VC more generally into the UK.

Gilead plans to develop HCXT-2001 both as a monotherapy and in combination with its own IBD hopeful, emvistegrast.

Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing the tumour microenvironment across immuno-oncology programmes ...

Pathos AI has secured $237m in a Series E round to expand its clinical oncology pipeline and scale its AI drug development platform.

With the AI revolution underway, sustainability is now a key consideration for pharma companies building and utilising data centres.

Numerous types of equity deals involving Chinese biotech, including the popular NewCo model, will be impacted by the proposed rule.

GSK's likely blockbuster-to-be led to a fifth of patients having undetectable viral levels in clinical trials.

AI Proteins and Astellas Innovation Management have signed a research collaboration and licence deal to discover and develop miniprotein therapeutics.

Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in a deal worth up to $580m.

The US FDA has approved Viatris' Ryzumvi (phentolamine ophthalmic solution 0.75%) to treat presbyopia in adults.